$6.88 -0.06 (-0.86%)
11/20/2009 4:00 PM

MannKind Corp (MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Current Price $6.88 Mkt Cap $776.11M
Open $7.12 P/E Ratio 0.00
Prev. Close $6.94 Div. (Yield) N/A (N/A)
Daily Range $6.81 - $7.24 Volume 1,394,735
52-Wk Range $2.00 - $12.30 Avg. Daily Vol. 1,913,000

MNKD News and Commentary

Caps

How do you think MNKD will perform vs the S&P 500?

Add Stock to Watchlist

All Members

343 Outperform
112 Underperform
 

All-Star Members

91 Outperform
44 Underperform
 

Wall Street

6 Outperform
3 Underperform
 

Top MNKD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

00buckshot (63.45)
Submitted November 12, 2009

The MNKD pipeline includes a market disrupting insulin product called Afresa that has been proven, in 40 clinical trials, in thousands of patients, over multiple years, to address diabetes in a way that reduces or eliminates the life and health… More

zzlangerhans (99.51)
Submitted May 07, 2009

I haven't had much luck lately taking on top-rated players on biotech stocks, as Demon took me to the cleaners on Dendreon and GMX spanked me on Arena and Repros. Since I refuse to learn a lesson about anything, ever, I'm going to now fly against… More

MNKD VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about MNKD.

Recs

0
Member Avatar MizzouFanVan (25.18) Submitted: 11/19/2009 12:37:05 PM : Outperform Start Price: $7.06 MNKD Score: -2.39

FDA should approve their inhaled insulin drug Afresa in January 2010 - could change a lot of people's lives - especially with Exubera (competitor inhaled insulin) taken off the shelves. Lots of upside potential here.

Recs

0
Member Avatar swingtrader88 (< 20) Submitted: 11/16/2009 8:18:07 PM : Outperform Start Price: $6.76 MNKD Score: +3.12

With the approval of Afresa this company will be an easy double. Once the label is clear, the big pharmas that have been courting them will fight for a marketing partnership. This couple with their cancer vaccine entering Phase 2 trails will secure Mannkinds place in the Biopharma world.
Never bet against Al Mann. He has sold 3 companies he founded for more than a billion personally.

Recs

1
Member Avatar 00buckshot (63.45) Submitted: 11/12/2009 10:07:10 AM : Outperform Start Price: $6.54 MNKD Score: +5.99

The MNKD pipeline includes a market disrupting insulin product called Afresa that has been proven, in 40 clinical trials, in thousands of patients, over multiple years, to address diabetes in a way that reduces or eliminates the life and health threatening glucose swings (including hypoglycemia), safely and effectively. Afresa changes the rules of diabetic treatment by allowing diabetics to maintain normal blood glucose levels simply, discreetly and without needles.

Diabetes affects approximately 170M humans worldwide and is increasing, with the WHO predicting 300 million diabetics by 2025. Global sales of diabetes drugs totaled US$27.3 billion last year, making diabetes the No. 4 drug class, according to IMS Health. Decision Resources, one of the world's leading research and advisory firms for pharmaceutical issues, surveyed U.S. and European endocrinologists and found that Afresa (a non-injectable, short-acting insulin with significantly improved efficacy over Novo Nordisk's NovoRapid/NovoLog) would earn a 50 percent patient share in type 1 diabetes alone in the United States and a 58 percent patient share in Europe. I peg current realistic value at closer to $20.

PDUFA date for Afresa is January 16th, and a partnership with a major pharmaceutical company appears inevitable at that time, with sales to begin by mid-year. This assessment totally ignores the value of the cancer vaccine pipeline and drug delivery platform licensing.

Leaderboard

Find the members with the highest scoring picks in MNKD.

Score Leader

Photizo

Photizo (23.20) Score: +342.75

The Score Leader is the member with the highest score across all their picks in MNKD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
Greatwhiteone 82.60 4/22/2008 Outperform NS $2.06 +233.98% -17.80% +251.78
bandofbrothers 78.10 4/22/2008 Outperform 3Y $2.09 +229.19% -17.55% +246.74 1 Comment
jonvaughn < 20 4/24/2008 Outperform 3M $2.11 +226.07% -17.80% +243.86
Mxpxrocks21 36.85 4/18/2008 Outperform 5Y $2.12 +224.53% -18.53% +243.06
JMC23 89.41 4/25/2008 Outperform 3M $2.17 +217.05% -18.62% +235.67
ckneville 72.95 4/17/2008 Outperform 3W $2.19 +214.16% -16.67% +230.83
Syfft 52.79 4/16/2008 Outperform 5Y $2.20 +212.73% -16.07% +228.80
bigpapalicious < 20 4/15/2008 Outperform 3W $2.22 +209.91% -14.73% +224.64
nbar 87.31 4/9/2008 9/24/2008 Outperform 3Y $2.24 +207.14% -16.12% +223.26
mikelm29 < 20 4/9/2008 Outperform NS $2.25 +205.78% -16.36% +222.14

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackOppenheimer < 20 9/26/2009 Underperform NS $9.59 -28.26% +4.44% +32.70
TrackLeerinkSwan 83.04 7/14/2009 Underperform NS $7.95 -13.46% +21.66% +35.11
TrackZacks 70.74 11/10/2008 Underperform 3M $3.64 +93.96% +1.32% -92.63 6/5/2009 @ $7.06 1 Comment
TrackRodmanRen < 20 10/7/2008 Outperform NS $3.58 +92.18% +5.11% +87.07
TrackJefferies 31.78 3/10/2008 Underperform NS $5.04 +36.51% -12.14% -48.65
TrackBillMiller < 20 9/30/2007 Outperform NS $9.68 -28.93% -24.86% -4.07 3 Comments
TrackZacks 70.74 9/11/2007 Underperform 3M $9.69 -64.91% -33.01% +31.91 10/20/2008 @ $3.40 1 Comment
TrackPatDorsey 71.52 7/6/2007 Outperform 5Y $13.09 -47.44% -24.69% -22.75
TrackBofASec 91.37 6/14/2007 Outperform NS $13.60 -49.41% -23.92% -25.49
TrackJefferies 31.78 3/8/2007 Outperform NS $15.53 -67.55% -7.83% -59.72 3/10/2008 @ $5.04
TrackJPMorgan 73.67 1/4/2007 Outperform NS $16.40 -47.26% +3.11% -50.37 11/9/2007 @ $8.65
TrackUBS 88.39 11/3/2006 Outperform NS $17.87 -61.50% -15.39% -46.11
TrackJimCramer 36.31 3/27/2006 Outperform 3W $20.67 -66.72% -9.80% -56.92

Featured Broker Partners